Safety Data Show Pain Drug as a Safe Alternative

DECEMBER 01, 2006
Susan Farley

Three phase 3 clinical trials of tramadol showed that the safety and efficacy of the once-daily formulation offers a safe alternative for the management of pain. The drug's manufacturer, Labopharm, presented data at the 17th Annual Clinical Meeting of the American Academy of Pain Management in September 2006. The 12-week, randomized, double-blind, placebo-controlled trials included 1763 patients with osteoarthritis of the knee. Doses ranging from 100 to 300 mg were randomized to 1095 patients, while 668 patients received placebo. The most frequent adverse events reported were nausea, constipation, dizziness/vertigo, somnolence, and vomiting. Adverse events appeared in at least 5% in all doses, but 90% of these events were reported to be mild or moderate. When compared with other formulations of tramadol, traditional opioids, and nonsteroidal anti-inflammatory drugs, the once-daily tramadol offered a safe alternative for pain management.

Ms. Farley is a freelance medical writer based in Wakefield, RI.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.